APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immuno-Oncology

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Selected research

Market Outlook & Growth Opportunities

Global Immuno-Oncology Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchImmuno-Oncology Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-Oncology Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Immuno-Oncology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-Oncology Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-Oncology Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.

This report provides an overview of the global Immuno-Oncology market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Immuno-Oncology and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immuno-Oncology revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Immuno-Oncology market.

Immuno-Oncology Segment by Company

Bristol-Myers Squibb

Merck & Co., Inc.

Roche AG

AstraZeneca, Plc

Sanofi S.A.

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc.

Merck KGaA

Immuno-Oncology Segment by Type

Immune Checkpoint Inhibitors

Cytokine-Based Immunotherapy

Cancer Vaccines

CAR-T Cell Therapy

Others

Immuno-Oncology Segment by Application

Hospitals

Drugstores

Others

Immuno-Oncology Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immuno-Oncology status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Immuno-Oncology key companies, revenue, market share, and recent developments.

3. To split the Immuno-Oncology breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Immuno-Oncology market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immuno-Oncology significant trends, drivers, influence factors in global and regions.

6. To analyze Immuno-Oncology competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immuno-Oncology industry.

Chapter 3: Detailed analysis of Immuno-Oncology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Immuno-Oncology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Immuno-Oncology in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immuno-Oncology Industry Trends Table 2. Immuno-Oncology Industry Drivers Table 3. Immuno-Oncology Industry Opportunities and Challenges Table 4. Immuno-Oncology Industry Restraints Table 5. Global Immuno-Oncology Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immuno-Oncology Revenue Share by Company (2021-2026) Table 7. Global Immuno-Oncology Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Immuno-Oncology Key Company Manufacturing Base & Headquarters Table 9. Global Immuno-Oncology Company, Product Type & Application Table 10. Global Immuno-Oncology Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Immuno-Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Immune Checkpoint Inhibitors Table 15. Significant Companies of Cytokine-Based Immunotherapy Table 16. Significant Companies of Cancer Vaccines Table 17. Significant Companies of CAR-T Cell Therapy Table 18. Significant Companies of Others Table 19. Global Immuno-Oncology Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Immuno-Oncology Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Immuno-Oncology Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Immuno-Oncology Sales Value Share by Type (2021-2026) Table 23. Global Immuno-Oncology Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Drugstores Table 26. Significant Companies of Others Table 27. Global Immuno-Oncology Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Immuno-Oncology Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Immuno-Oncology Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Immuno-Oncology Sales Value Share by Application (2021-2026) Table 31. Global Immuno-Oncology Sales Value Share by Application (2027-2032) Table 32. Global Immuno-Oncology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Immuno-Oncology Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Immuno-Oncology Sales Value Share by Region (2021-2026) Table 35. Global Immuno-Oncology Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Immuno-Oncology Sales Value Share by Region (2027-2032) Table 37. Global Immuno-Oncology Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Immuno-Oncology Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Immuno-Oncology Sales Value Market Share by Country (2021-2026) Table 40. Global Immuno-Oncology Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Immuno-Oncology Sales Value Market Share by Country (2027-2032) Table 42. Bristol-Myers Squibb Company Information Table 43. Bristol-Myers Squibb Business Overview Table 44. Bristol-Myers Squibb Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Bristol-Myers Squibb Immuno-Oncology Product Portfolio Table 46. Bristol-Myers Squibb Recent Development Table 47. Merck & Co., Inc. Company Information Table 48. Merck & Co., Inc. Business Overview Table 49. Merck & Co., Inc. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Merck & Co., Inc. Immuno-Oncology Product Portfolio Table 51. Merck & Co., Inc. Recent Development Table 52. Roche AG Company Information Table 53. Roche AG Business Overview Table 54. Roche AG Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Roche AG Immuno-Oncology Product Portfolio Table 56. Roche AG Recent Development Table 57. AstraZeneca, Plc Company Information Table 58. AstraZeneca, Plc Business Overview Table 59. AstraZeneca, Plc Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. AstraZeneca, Plc Immuno-Oncology Product Portfolio Table 61. AstraZeneca, Plc Recent Development Table 62. Sanofi S.A. Company Information Table 63. Sanofi S.A. Business Overview Table 64. Sanofi S.A. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sanofi S.A. Immuno-Oncology Product Portfolio Table 66. Sanofi S.A. Recent Development Table 67. Dendreon Pharmaceuticals Company Information Table 68. Dendreon Pharmaceuticals Business Overview Table 69. Dendreon Pharmaceuticals Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio Table 71. Dendreon Pharmaceuticals Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Novartis Immuno-Oncology Product Portfolio Table 76. Novartis Recent Development Table 77. Gilead Sciences Inc. Company Information Table 78. Gilead Sciences Inc. Business Overview Table 79. Gilead Sciences Inc. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Gilead Sciences Inc. Immuno-Oncology Product Portfolio Table 81. Gilead Sciences Inc. Recent Development Table 82. Merck KGaA Company Information Table 83. Merck KGaA Business Overview Table 84. Merck KGaA Immuno-Oncology Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Merck KGaA Immuno-Oncology Product Portfolio Table 86. Merck KGaA Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Immuno-Oncology Product Image Figure 2. Global Immuno-Oncology Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 4. Global Immuno-Oncology Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Immune Checkpoint Inhibitors Image Figure 8. Cytokine-Based Immunotherapy Image Figure 9. Cancer Vaccines Image Figure 10. CAR-T Cell Therapy Image Figure 11. Others Image Figure 12. Global Immuno-Oncology Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Immuno-Oncology Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Immuno-Oncology Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Drugstores Image Figure 17. Others Image Figure 18. Global Immuno-Oncology Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Immuno-Oncology Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Immuno-Oncology Sales Value Share by Application (2021-2032) Figure 21. Global Immuno-Oncology Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Immuno-Oncology Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Immuno-Oncology Sales Value (2021-2032) & (US$ Million) Figure 24. North America Immuno-Oncology Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Immuno-Oncology Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Immuno-Oncology Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Immuno-Oncology Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Immuno-Oncology Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Immuno-Oncology Sales Value (2021-2032) & (US$ Million) Figure 30. South America Immuno-Oncology Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Immuno-Oncology Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Immuno-Oncology Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Immuno-Oncology Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Immuno-Oncology Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Immuno-Oncology Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Checkpoint Inhibitors
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy
  • Others
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Roche AG
  • AstraZeneca, Plc
  • Sanofi S.A.
  • Dendreon Pharmaceuticals
  • Novartis
  • Gilead Sciences Inc.
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immuno-Oncology Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immuno-Oncology Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Immuno-Oncology Market Dynamics
  1. 2.1 Immuno-Oncology Industry Trends
  2. 2.2 Immuno-Oncology Industry Drivers
  3. 2.3 Immuno-Oncology Industry Opportunities and Challenges
  4. 2.4 Immuno-Oncology Industry Restraints
3 Immuno-Oncology Market by Company
  1. 3.1 Global Immuno-Oncology Company Revenue Ranking in 2025
  2. 3.2 Global Immuno-Oncology Revenue by Company (2021-2026)
  3. 3.3 Global Immuno-Oncology Company Ranking (2024-2026)
  4. 3.4 Global Immuno-Oncology Company Manufacturing Base and Headquarters
  5. 3.5 Global Immuno-Oncology Company Product Type and Application
  6. 3.6 Global Immuno-Oncology Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Immuno-Oncology Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Immuno-Oncology Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Immuno-Oncology Market by Type
  1. 4.1 Immuno-Oncology Type Introduction
  2. 4.1.1 Immune Checkpoint Inhibitors
  3. 4.1.2 Cytokine-Based Immunotherapy
  4. 4.1.3 Cancer Vaccines
  5. 4.1.4 CAR-T Cell Therapy
  6. 4.1.5 Others
  7. 4.2 Global Immuno-Oncology Sales Value by Type
  8. 4.2.1 Global Immuno-Oncology Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Immuno-Oncology Sales Value by Type (2021-2032)
  10. 4.2.3 Global Immuno-Oncology Sales Value Share by Type (2021-2032)
5 Immuno-Oncology Market by Application
  1. 5.1 Immuno-Oncology Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Immuno-Oncology Sales Value by Application
  6. 5.2.1 Global Immuno-Oncology Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Immuno-Oncology Sales Value by Application (2021-2032)
  8. 5.2.3 Global Immuno-Oncology Sales Value Share by Application (2021-2032)
6 Immuno-Oncology Regional Value Analysis
  1. 6.1 Global Immuno-Oncology Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immuno-Oncology Sales Value by Region (2021-2032)
  3. 6.2.1 Global Immuno-Oncology Sales Value by Region: 2021-2026
  4. 6.2.2 Global Immuno-Oncology Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immuno-Oncology Sales Value (2021-2032)
  7. 6.3.2 North America Immuno-Oncology Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Immuno-Oncology Sales Value (2021-2032)
  10. 6.4.2 Europe Immuno-Oncology Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Immuno-Oncology Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Immuno-Oncology Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Immuno-Oncology Sales Value (2021-2032)
  16. 6.6.2 South America Immuno-Oncology Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Immuno-Oncology Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Immuno-Oncology Sales Value Share by Country, 2025 VS 2032
7 Immuno-Oncology Country-level Value Analysis
  1. 7.1 Global Immuno-Oncology Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immuno-Oncology Sales Value by Country (2021-2032)
  3. 7.2.1 Global Immuno-Oncology Sales Value by Country (2021-2026)
  4. 7.2.2 Global Immuno-Oncology Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Immuno-Oncology Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Immuno-Oncology Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Immuno-Oncology Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Immuno-Oncology Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Immuno-Oncology Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Immuno-Oncology Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Immuno-Oncology Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Immuno-Oncology Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Immuno-Oncology Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Immuno-Oncology Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Immuno-Oncology Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Immuno-Oncology Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Immuno-Oncology Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Immuno-Oncology Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Immuno-Oncology Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Immuno-Oncology Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Immuno-Oncology Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Immuno-Oncology Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Immuno-Oncology Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Immuno-Oncology Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Immuno-Oncology Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Immuno-Oncology Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Immuno-Oncology Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Immuno-Oncology Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Immuno-Oncology Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Immuno-Oncology Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Immuno-Oncology Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Immuno-Oncology Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Immuno-Oncology Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Immuno-Oncology Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Immuno-Oncology Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Immuno-Oncology Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Immuno-Oncology Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Immuno-Oncology Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Roche AG
  14. 8.3.1 Roche AG Company Information
  15. 8.3.2 Roche AG Business Overview
  16. 8.3.3 Roche AG Immuno-Oncology Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche AG Immuno-Oncology Product Portfolio
  18. 8.3.5 Roche AG Recent Developments
  19. 8.4 AstraZeneca, Plc
  20. 8.4.1 AstraZeneca, Plc Company Information
  21. 8.4.2 AstraZeneca, Plc Business Overview
  22. 8.4.3 AstraZeneca, Plc Immuno-Oncology Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca, Plc Immuno-Oncology Product Portfolio
  24. 8.4.5 AstraZeneca, Plc Recent Developments
  25. 8.5 Sanofi S.A.
  26. 8.5.1 Sanofi S.A. Company Information
  27. 8.5.2 Sanofi S.A. Business Overview
  28. 8.5.3 Sanofi S.A. Immuno-Oncology Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi S.A. Immuno-Oncology Product Portfolio
  30. 8.5.5 Sanofi S.A. Recent Developments
  31. 8.6 Dendreon Pharmaceuticals
  32. 8.6.1 Dendreon Pharmaceuticals Company Information
  33. 8.6.2 Dendreon Pharmaceuticals Business Overview
  34. 8.6.3 Dendreon Pharmaceuticals Immuno-Oncology Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio
  36. 8.6.5 Dendreon Pharmaceuticals Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Immuno-Oncology Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Immuno-Oncology Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Gilead Sciences Inc.
  44. 8.8.1 Gilead Sciences Inc. Company Information
  45. 8.8.2 Gilead Sciences Inc. Business Overview
  46. 8.8.3 Gilead Sciences Inc. Immuno-Oncology Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gilead Sciences Inc. Immuno-Oncology Product Portfolio
  48. 8.8.5 Gilead Sciences Inc. Recent Developments
  49. 8.9 Merck KGaA
  50. 8.9.1 Merck KGaA Company Information
  51. 8.9.2 Merck KGaA Business Overview
  52. 8.9.3 Merck KGaA Immuno-Oncology Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck KGaA Immuno-Oncology Product Portfolio
  54. 8.9.5 Merck KGaA Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst